Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

…, HM Kantarjian, J Cortes, M Beran, CA Koller… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To assess the efficacy of combination therapy with fludarabine and cyclophosphamide
in patients with chronic lymphocytic leukemia (CLL) based on data suggesting in vitro …

The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia

…, FJ Giles, A Dey, Z Estrov, CA Koller… - Blood, The Journal …, 2002 - ashpublications.org
Tumor necrosis factor-α (TNF-α), a cytokine possessing pleiotropic biological activities, is
produced by leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL) and …

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

…, J Cortes, FJ Giles, WG Wierda, CA Koller… - Cancer, 2003 - Wiley Online Library
BACKGROUND The objective of this study was to investigate the efficacy and safety of
alemtuzumab, the humanized anti‐CD52 monoclonal antibody, in patients with B‐cell chronic …

[HTML][HTML] Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

…, J Cortes, D Thomas, CA Koller… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse;
some patients have indolent disease, never needing treatment, whereas others have …

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

…, MB Rios, FJ Giles, M Beran, CA Koller… - … Journal of the …, 1999 - Wiley Online Library
BACKGROUND The prognoses of patients with chronic myelogenous leukemia in blastic
phase (CML‐BP) are extremely poor. Treatment of patients with nonlymphoid CML‐BP is …

Eradication of minimal residual disease in hairy cell leukemia

…, JL Jorgensen, SM O'Brien, S Verstovsek, CA Koller… - Blood, 2006 - ashpublications.org
Although the nucleoside analogs cladribine and pentostatin produce high response rates in
patients with hairy cell leukemia (HCL), a significant number of patients eventually relapse. …

High‐dose chemotherapy in high‐risk myelodysplastic syndrome: Covariate‐adjusted comparison of five regimens

M Beran, Y Shen, H Kantarjian, S O'Brien, CA Koller… - Cancer, 2001 - Wiley Online Library
BACKGROUND Antileukemic chemotherapy has been used for two decades to treat high‐risk
myelodysplastic syndrome (refractory anemia with excess of blasts [RAEB] and RAEB in …

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

…, E Estey, S O'Brien, J Cortes, CA Koller… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: To evaluate the efficacy and safety of the combination of topotecan and
cytarabine in patients with myelodysplastic syndromes (MDSs) and chronic myelomonocytic …

Combination therapy with arsenic trioxide, all‐trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia

…, HM Kantarjian, EH Estey, CA Koller… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. From 20% to 30% of patients with acute promyelocytic leukemia (APL) who
are treated with all‐trans retinoic acid (ATRA) develop recurrent disease. Arsenic trioxide (…

The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia

CA Koller, HM Kantarjian, D Thomas, S O'Brien… - Leukemia, 1997 - nature.com
Sixty-six adults with refractory acute lymphocytic leukemia received salvage therapy with
the ‘hyper-CVAD’regimen, consisting of eight courses of alternating intensive chemotherapy …